MET and non-small cell lung carcinoma: However, due to the lack of solid clinical evidence derived from a larger cohort or a controlled clinical trial, there is still no consensus on the standard treatment for patients with advanced EGFR-mutant NSCLC who acquire MET amplification during EGFR-TKI therapy.